Cardiac Arrest Following Remimazolam-Induced Anaphylaxis: A Case Report

Remimazolam is a recently approved benzodiazepine sedative. We report a case of a 72-year-old man who experienced a cardiac arrest due to severe anaphylaxis immediately after general anesthesia induction. Based on the results of skin tests, including those for dextran 40, an excipient in the remimaz...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasushita, Yudai, Nagao, Megumi, Miyazawa, Yoshihide, Yunoki, Kazuma, Mima, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Cardiovascular Anesthesiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521581/
https://www.ncbi.nlm.nih.gov/pubmed/36149988
http://dx.doi.org/10.1213/XAA.0000000000001616
Descripción
Sumario:Remimazolam is a recently approved benzodiazepine sedative. We report a case of a 72-year-old man who experienced a cardiac arrest due to severe anaphylaxis immediately after general anesthesia induction. Based on the results of skin tests, including those for dextran 40, an excipient in the remimazolam solution, and a review of drugs given during 3 anesthetics, remimazolam was identified as the probable causative agent. Although remimazolam is structurally similar to midazolam, the patient was not allergic to midazolam as demonstrated before and after anaphylaxis. This report highlights the potential risk of allergic reactions to remimazolam.

Ejemplares similares